
|Articles|January 10, 2005
Implant provides long-acting treatment for prostate cancer
Luteinizing hormone-releasing hormone (LHRH) agonists are a mainstay in treating locally advanced and metastatic prostate cancer, with the U.S. market for these therapies representing more than $1 billion in annual sales. The market is dominated by four-month and shorter depot injections and implants, such as leupro-lide acetate (Lupron, TAP Pharmaceuticals) for depot suspension and goserelin acetate (Zoladex, Astra Zeneca) implant.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Targeted Coordination Is Crucial in Boosting Pneumococcal Vaccine Coverage
2
CoronaVac Improves Outcomes of COVID-19 for Patients With Schizophrenia
3
Reducing HIV Stigma Can Improve Patient Care, Provider Connectivity
4
Harps Food Train Pharmacists to Confidently Prescribe Birth Control
5
















































































































